Inhibikase Therapeutics, Inc. Ratios

Ratios Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -407.73%-476.88%-14,686.17%-7,711.98%
EBIT Margin -403.52%-476.23%-14,686.17%-7,711.98%
EBITDA Margin -403.52%-476.23%-14,686.17%-7,711.98%
Operating Margin -403.52%-476.23%-14,686.17%-7,711.98%
Net Margin -407.73%-476.88%-14,686.17%-7,711.98%
FCF Margin -161.69%-461.11%-14,253.37%-6,947.87%
Efficiency
Assets Average 28.63M33.70M19.72M56.55M
Equity Average 24.10M29.73M16.01M52.92M
Invested Capital 9.78M38.42M21.18M11.36M94.98M
Asset Utilization Ratio 0.110.000.01
Leverage & Solvency
Interest Coverage Ratio -95.86-741.16
Debt to Equity 0.030.010.010.00
Debt Ratio 0.020.010.010.00
Equity Ratio 0.660.900.840.760.96
Times Interest Earned -95.86-741.16
Valuation
Enterprise Value 52.32M-3.77M-10.44M-5.41M120.83M
Market Capitalization 66.28M36.98M12.61M7.84M218.38M
Return Ratios
Return on Sales -4.08%-4.77%-146.86%-77.12%
Return on Capital Employed -0.60%-0.60%-1.23%-0.54%
Return on Assets -0.52%-0.54%-1.02%-0.51%
Return on Equity -0.61%-0.61%-1.26%-0.54%